STAAR Surgical Company (STAA) Set to Announce Earnings on Wednesday
STAAR Surgical Company (NASDAQ:STAA) is scheduled to release its earnings data after the market closes on Wednesday, November 1st. Analysts expect STAAR Surgical to post earnings of ($0.04) per share for the quarter.
STAAR Surgical (NASDAQ:STAA) last posted its earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.04. STAAR Surgical had a negative net margin of 6.06% and a negative return on equity of 8.69%. The firm had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $22.15 million. During the same period in the previous year, the business posted ($0.02) EPS. The business’s revenue was up 4.8% compared to the same quarter last year. On average, analysts expect STAAR Surgical to post $-0.03 EPS for the current fiscal year and $0.19 EPS for the next fiscal year.
STAAR Surgical Company (STAA) opened at 12.80 on Wednesday. The firm’s market capitalization is $526.18 million. The company has a 50 day moving average of $12.42 and a 200 day moving average of $10.83. STAAR Surgical Company has a 1-year low of $7.45 and a 1-year high of $13.95.
A number of equities analysts recently weighed in on STAA shares. Zacks Investment Research upgraded shares of STAAR Surgical from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Canaccord Genuity reiterated a “buy” rating and issued a $15.00 price objective on shares of STAAR Surgical in a research report on Sunday, October 8th. Benchmark Co. lifted their price objective on shares of STAAR Surgical from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, October 20th. BidaskClub upgraded shares of STAAR Surgical from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Finally, TheStreet upgraded shares of STAAR Surgical from a “d+” rating to a “c” rating in a research report on Tuesday, August 15th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $14.00.
About STAAR Surgical
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.
Receive News & Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related companies with MarketBeat.com's FREE daily email newsletter.